Merck news
The WiseView Research desk's stories that name Merck, the latest headlines about it, and the trades members of Congress and company insiders have disclosed. The MRK page →
- HeadlineBrokers Suggest Investing in Merck (MRK): Read This Before Placing a Bet
- HeadlineIs Merck Stock a Buy, Sell or Hold Ahead of Q3 Earnings?
- HeadlineMerck Highlights Phase III Cancer Wins, Eyes 2027 Oncology Pipeline Catalysts
- HeadlineMerck & Co., Inc. (MRK) Shareholder/Analyst Call Transcript
- HeadlineCountdown to Merck (MRK) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
- HeadlineBeyond Keytruda: The Critical Pipeline Metrics to Watch in Merck's Q3 Results on Oct. 29
- HeadlineMerck (MRK) Laps the Stock Market: Here's Why
- HeadlineMerck (MRK) Stock Dips While Market Gains: Key Facts
- HeadlineSilence Therapeutics jumps 59% on Merck takeover
- CongressMichael McCaul sold $50,001 - $100,000 of MRK
- HeadlineWill Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?
- HeadlineMerck (MRK) Dips More Than Broader Market: What You Should Know
- HeadlineMerck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026
- HeadlineJefferies cuts Merck's remigromig sales forecast after eye-disease trial raises concerns
- HeadlineWall Street Bulls Look Optimistic About Merck (MRK): Should You Buy?
- HeadlineMerck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026
- CongressRo Khanna sold $1,001 - $15,000 of MRK
- HeadlineMerck's Keytruda Is Dealt a Legal Setback. It's Good News for This Biotech Stock.
- HeadlineMerck (MRK) Beats Stock Market Upswing: What Investors Need to Know
- HeadlineMerck Stock Down 7% in a Month: Is the Dip a Buying Opportunity?
- HeadlineMerck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study
- HeadlineMerck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29
- HeadlineWhy Merck (MRK) Dipped More Than Broader Market Today
- HeadlineMerck says experimental skin disease drug meets main goal in mid-stage study
- HeadlineMerck Inks $2.1B Deal With Chinese Biotech to Expand Oncology Pipeline
- HeadlineMerck Turned $1,000 Into $3,395 in a Decade but the Real Story Happened in the Last Year
- CongressRo Khanna bought $15,001 - $50,000 of MRK
- CongressKeith Self sold $1,001 - $15,000 of MRK
- CongressJosh Gottheimer bought $1,001 - $15,000 of MRK
- CongressMichael McCaul sold $15,001 - $50,000 of MRK
- CongressJulie Johnson sold $1,001 - $15,000 of MRK
- CongressGilbert Cisneros bought $1,001 - $15,000 of MRK
Headlines link to their publishers. Members of Congress disclose ranges, not exact amounts, and may file weeks after the trade; insider filings are open-market purchases and sales from SEC Form 4. For information only, not investment advice.